Pd38-05 is routine antibiotic prophylaxis required for transperineal prostate biopsy?

You have accessJournal of UrologyCME1 Apr 2023PD38-05 IS ROUTINE ANTIBIOTIC PROPHYLAXIS REQUIRED FOR TRANSPERINEAL PROSTATE BIOPSY? Apoorv Dhir, Alexander Zhu, Ji Qi, Stephanie Ferrante, Kevin Ginsburg, Alice Semerjian, Craig Rogers, Amit Patel, Brian Stork, Arvin George, and For the Michigan Urological Surgery Improvement Collaborative Apoorv DhirApoorv Dhir More articles by this author , Alexander ZhuAlexander Zhu More articles by this author , Ji QiJi Qi More articles by this author , Stephanie FerranteStephanie Ferrante More articles by this author , Kevin GinsburgKevin Ginsburg More articles by this author , Alice SemerjianAlice Semerjian More articles by this author , Craig RogersCraig Rogers More articles by this author , Amit PatelAmit Patel More articles by this author , Brian StorkBrian Stork More articles by this author , Arvin GeorgeArvin George More articles by this author , and For the Michigan Urological Surgery Improvement Collaborative More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003336.05AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Transperineal prostate biopsy (TPBx) has successfully reduced the risk of infectious complications compared to the transrectal approach. Contemporary guidelines continue to recommend antibiotic prophylaxis due to potential rectal/skin flora contamination or entry into the urinary tract; however, this inherently risks escalating antimicrobial resistance. We sought to evaluate the current practice patterns of antibiotic prophylaxis (ATB) for TPBx and the associated rates of infectious complications. METHODS: Men in the Michigan Urological Surgery Improvement Collaborative (MUSIC) prostate cancer registry who underwent non-fusion (systematic) TPBx between 2017 and 2022 were analyzed. Patient demographics, disease characteristics, and peri-procedural outcomes were assessed. The primary outcome was infectious complications after TPBx. Infections were defined as fever, sepsis, and/or UTI. RESULTS: We identified 2212 men who underwent non-fusion (systematic) TPBx in the study period, 669 (30%) of whom did not receive ATB for TPBx (Table 1). The yearly percentage of patients with no ATB rose from 0.81% in 2017 to 65.6% in 2022 (Figure 1). Between patients with ATB and no ATB, there were no statistically significant difference in rates of infection (0.65% vs 0.45%, p=0.77) or infectious hospitalizations (0.32% vs 0.45%, p=0.70). CONCLUSIONS: Use of antibiotic prophylaxis for TPBx has decreased over time in the state of Michigan. Antibiotic prophylaxis was not associated with rates of infection and infectious hospitalizations after transperineal fusion biopsy. Source of Funding: funding from Blue Cross Blue Shield of Michigan © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e994 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Apoorv Dhir More articles by this author Alexander Zhu More articles by this author Ji Qi More articles by this author Stephanie Ferrante More articles by this author Kevin Ginsburg More articles by this author Alice Semerjian More articles by this author Craig Rogers More articles by this author Amit Patel More articles by this author Brian Stork More articles by this author Arvin George More articles by this author For the Michigan Urological Surgery Improvement Collaborative More articles by this author Expand All Advertisement PDF downloadLoading ...